ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA, a Switzerland-based commercial-stage biotechnology company, furnished this Form 6-K for October 2021. On October 29, 2021, the company announced that the European Medicines Agency validated its Marketing Authorization Application for ZYNLONTA® (loncastuximab tesirine-lpyl), enabling review by the EMA’s Committee for Medicinal Products for Human Use.
Key clinical and financial information
The filing is an announcement regarding regulatory progress and does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial statement metrics. The MAA is supported by the Phase 2 LOTIS-2 trial in 145 adults with relapsed or refractory diffuse large B-cell lymphoma after at least two prior systemic therapies.
| Measure | Reported result |
|---|---|
| Overall response rate | 48.3% (70 of 145 patients) |
| Complete response rate | 24.1% (35 of 145 patients) |
| Partial response rate | 24.1% (35 of 145 patients) |
| Median time to response | 1.3 months |
| Median duration of response | 13.4 months at the latest data cutoff described |
Common adverse reactions in the pooled safety population included thrombocytopenia, elevated gamma-glutamyltransferase, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, and musculoskeletal pain. The most common grade 3 or higher treatment-emergent events in LOTIS-2 were neutropenia (26.2%), thrombocytopenia (17.9%), elevated gamma-glutamyltransferase (17.2%), and anemia (10.3%).
Material changes versus the prior comparable period
The filing does not provide a prior-period financial or operating comparison. The principal development during the period was EMA validation of the ZYNLONTA MAA. This followed FDA accelerated approval in April 2021 for adult patients with relapsed or refractory large B-cell lymphoma after two or more systemic therapies and European Commission Orphan Drug Designation in September 2021 for DLBCL.
Guidance, outlook, risks, and unusual items
- EMA validation permits the formal regulatory evaluation; it does not represent marketing authorization or guarantee approval.
- ZYNLONTA’s U.S. approval is under the FDA accelerated approval pathway. Continued approval may depend on verification and description of clinical benefit in a confirmatory trial.
- The company is evaluating ZYNLONTA in combination studies and earlier lines of therapy.
- Camidanlumab tesirine is in a late-stage trial for relapsed or refractory Hodgkin lymphoma and a Phase 1b trial for advanced solid tumors; additional ADC programs are in clinical and preclinical development.
- The heavily pre-treated LOTIS-2 population and reported treatment-related adverse events indicate material clinical and safety risks.
Important facts for investors to verify
- Whether the EMA ultimately grants marketing authorization and the timing and terms of any decision.
- Progress, results, and regulatory implications of the confirmatory trial required under the U.S. accelerated approval.
- Commercial launch performance, reimbursement, demand, and sales of ZYNLONTA, which are not addressed in this filing.
- Updated safety, duration-of-response, and confirmatory efficacy data from LOTIS-2 and subsequent studies.
- The company’s financial position, cash runway, debt, liquidity, and operating results, none of which are provided in this Form 6-K.